ABX-196 is under clinical development by Abivax and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ABX-196’s likelihood of approval (LoA) and phase transition for Bladder Cancer took place on 18 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 18 Dec 2020 increased ABX-196’s LoA and PTSR for Cervical Cancer, increased LoA and PTSR for Chlamydia Infections, increased LoA and PTSR for Dengue Fever, increased PTSR for Hepatocellular Carcinoma, increased LoA and PTSR for Human Papillomavirus (HPV) Associated Cancer, increased LoA and PTSR for Japanese Encephalitis, increased LoA and PTSR for Melanoma, increased LoA and PTSR for Respiratory Syncytial Virus (RSV) Infections, and increased PTSR for Seasonal Influenza.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ABX-196 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ABX-196 overview

ABX-196 is under development as an adjuvant for the treatment of respiratory syncytial virus (RSV) infections, genital herpes, chlamydia infections, dengue, influenza (seasonal) and cancers including melanoma, cervix cancer, bladder cancer, human papillomavirus associated with cancer and hepatocellular carcinoma. It is administered by intramuscular route. The therapeutic candidate is a synthetic analog of glycolipid a-galactosylceramide (a-GalCer). It is developed based on Immune enhancer platform. It was also under development for hepatitis B infections.

It was under development for Influenza A virus, H5N1 subtype infections and pandemic influenza.

Abivax overview

Abivax operates as a biotechnology company. It develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company offers pipeline products that include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus infection. The company also develops various technology platforms including antiviral platform, immune enhancer platform and polyclonal antibody platform. Abivax is headquartered in Paris, France.

Quick View ABX-196 LOA Data

Report Segments
  • Innovator
Drug Name
  • ABX-196
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.